Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01968213 · OUTCOME

Overall Survival (OS)

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) · Source last updated 2023-06-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
All patients were followed for survival up to approximately 8.2 years.

What was measured

Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.

Analysis population: Intent-to-treat: All patients randomized

Groups in this outcome

Rucaparib 600 mg Tablets

Taken orally twice daily (continuous 28 day treatment cycles)

Placebo Tablets

Taken orally twice daily (continuous 28 day treatment cycles)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rucaparib 600 mg Tablets375
Placebo Tablets189

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Rucaparib 600 mg Tablets36.0Not reported32.839.4Not reported
Placebo Tablets43.2Not reported38.146.9Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        32.8
        upper Limit
        39.4
        value
        36.0
      2. group Id
        OG001
        lower Limit
        38.1
        upper Limit
        46.9
        value
        43.2
denoms
  1. counts
    1. group Id
      OG000
      value
      375
    2. group Id
      OG001
      value
      189
    units
    Participants
description
Overall survival (OS) is defined as the number of days from the date of randomization to the date of death (due to any cause). Patients who are still alive were censored on the date of their last available visit or last date known to be alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Taken orally twice daily (continuous 28 day treatment cycles)
    id
    OG000
    title
    Rucaparib 600 mg Tablets
  2. description
    Taken orally twice daily (continuous 28 day treatment cycles)
    id
    OG001
    title
    Placebo Tablets
param Type
MEDIAN
population Description
Intent-to-treat: All patients randomized
reporting Status
POSTED
time Frame
All patients were followed for survival up to approximately 8.2 years.
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice